Chemical Namerelugolix
Dosage FormTablets (oral; 120 mg)
Drug ClassReceptor antagonists
SystemMale reproductive
CompanyMyovant Sciences, Inc.
Approval Year2020


  • Indicated for the treatment of adult patients with advanced prostate cancer.
Last updated on 1/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Orgovyx (relugolix) Prescribing Information.2020Myovant Sciences, Inc., Brisbane, CA
Document TitleYearSource
Oral relugolix for androgen-deprivation therapy in advanced prostate cancer.2020The New England Journal of Medicine